Table 3 Meta-regression analyses for MACE and net clinical benefit
| Â | MACE | Net clinical benefit | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | p | Adj-R2 (%) | I2 (%) | Tau2 | p | Adj-R2 (%) | I2 (%) | Tau2 |
Percentage of ACS | 0.028 | 7.59 | 54.65 | 0.3979 | 0.211 | 0 | 54.62 | 0.4356 |
Age | 0.229 | 0 | 70.27 | 0.456 | 0.195 | 8.99 | 50.75 | 0.2937 |
Verifynow cutoff value | 0.566 | 0 | 22.14 | 0 | 0.864 | 0 | 20.59 | 0.1935 |
Study size | 0.005 | 44.13 | 46.13 | 0.2406 | 0.032 | 4.91 | 66.22 | 0.3069 |
Follow up | 0.077 | 22.45 | 60.23 | 0.3181 | 0.022 | 61.72 | 40.97 | 0.1219 |
Intervention duration | 0.005 | 76.06 | 36.87 | 0.09818 | 0.006 | 86.69 | 18.98 | 0.04239 |